Skip to product information
1 of 1

FDA NDA 201094, GLYDO, SAGENT PHARMS INC, 04/28/2014

FDA NDA 201094, GLYDO, SAGENT PHARMS INC, 04/28/2014

Regular price $89.00 USD
Regular price Sale price $89.00 USD
Sale Sold out

Contents: Summary Basis of Approval (SBOA) of GLYDO (Lidocaine Hydrochloride) jelly 2% held by Sagent Pharmaceuticals INC.

NDA: 201094
Company: SAGENT PHARMS INC
Drug Name: GLYDO
Active Ingredients: LIDOCAINE HYDROCHLORIDE
Strength: 2%
Dosage Form/Route: JELLY;TOPICAL
Action Date: 04/28/2014
Marketing Status: Prescription
Submission Classification: ORIG-1
Action Date:  04/28/2014

273 Pages

View full details
FOIA Pro

This drug has a lot more FDA history than one product page can show

FOIA Pro gives you full-text search across 70,000+ FDA FOIA records, from 2020 through today, plus a monthly monitor tracking new requests as they close.
  • Full-text search across every FDA FOIA log since 2020
  • Warning letters, approval records, and correspondence in one place
  • Monthly FDA FOIA Monitor newsletter, included
  • Cancel anytime, monthly or annual billing
Get FOIA Pro
Live search · FOIA database
Searching related FDA records…
ClosedTypeSubjectOutcome